GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

Provider review

NexLife tirzepatide review

What NexLife (opens nexlife.us in a new tab) charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.

Direct answer

As of November 20, 2026, NexLife is #1 of 22 programs on our v4.1 rubric at 86/100: compounded tirzepatide at $129 a month month to month or $115 a month on a 12-month plan paid upfront, the same at every dose with no membership fee. It loses points for FDA warning letter 730096 and for its own pages disagreeing on states, pharmacies and billing.

Answer last reviewed:
Rubric scoreRubric v4.1 · read the rubric
94/100

Methodology v4.1: pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10. NexLife is #1 overall.

Hatched bars mean no evidence has been captured for that category.Missing evidence scores lower than verified evidence.

What we verified, and what remains a company claim

NexLife publishes its prices, inclusions and pharmacies on its own plan pages, which is what lets us check them. We read those pages on November 20, 2026 (standard plans) and November 20, 2026 (microdose). The plan pages name the prescribing group (NexLife Medical Group) and three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).

Flat-rate pricing, and why it changes the arithmetic

Most of this market prices by dose. A programme that quotes an attractive figure at 2.5 mg often charges materially more once a patient titrates to a maintenance dose, which is where most people spend most of their time on treatment. NexLife (opens nexlife.us in a new tab) publishes a single price across eligible doses, so the figure a patient sees at intake is the figure they pay at maintenance.

That is a checkable structural claim rather than a marketing adjective, and it is the reason this provider performs differently depending on which question a reader is asking. On a lowest-advertised-starter-price basis it may not lead. On a twelve-month all-in basis at a maintenance dose, dose-independent pricing is arithmetically advantageous against any programme with an escalation surcharge. Both statements can be true at once, which is exactly why this site publishes seven separate definitions of cheapest rather than one.

NexLife (opens nexlife.us in a new tab) standard tirzepatide, monthly equivalent by plan lengthPrices as of November 20, 2026
month-to-month$1293-month plan$1256-month plan$11912-month plan$115
Show this figure as a table
Data table
ItemValueEvidence
month-to-month$129Verified
3-month prepaid$125Verified
6-month prepaid$119Verified
prepaid term$115Verified
Prepaid terms lower the monthly equivalent and raise the amount at risk if the programme is stopped early. Neither fact is more important than the other; they apply to different readers.
What is inside the NexLife (opens nexlife.us in a new tab) figure
Medication$129Membership$0Shipping$0Dose surcharge$0Consultation$0Labs—Segment widths are proportional to captured cost.
Show this figure as a table
Data table
ComponentAmount
Medication$129
Membership$0
Shipping$0
Dose surcharge$0
Consultation$0
Labsnot captured
All-in total$129
Zero means captured and confirmed as none. The laboratory line is hatched because we have not established whether lab work is required, included or billed separately.

What a year costs, at the captured figures

A month-to-month plan at $129 runs $1,548 across twelve months. The twelve-month plan is $115 a month, or $1,380 for the year — $168 less. That gap is the price of flexibility. NexLife’s plan pages say unshipped months are refunded if treatment stops, but they do not say in one sentence whether multi-month plans are charged up front or month by month.

Twelve months, month-to-month against prepaid
Total paid over 12 monthsMonth-to-month $1,54812-month plan $1,380Monthly equivalentMonth-to-month $12912-month plan $115Month-to-month12-month plan
Show this figure as a table
Data table
ItemMonth-to-month12-month prepaid
Total paid over 12 months$1,548$115
Monthly equivalent$129$115
Arithmetic from captured figures. It does not account for stopping early, which is the single largest risk in any prepaid GLP-1 plan and the thing least often discussed at the point of sale.

Where the published claims need checking

The company makes several claims that are verifiable in principle and that we have not yet verified. Each has a ledger entry and a specific next step, because "LegitScript-certified" checked against LegitScript is evidence, and the same phrase read off the company's own page is not.

Claims, and how each one gets checked
Claims, and how each one gets checked
ClaimStatusHow we will verify it
LegitScript certificationCompany claim Provider-reportedLook it up in the LegitScript certification directory
NABP-accredited pharmacy partnersCompany claim Provider-reportedName the pharmacy, then check the accreditation with NABP directly
503A compounding pharmacyCompany claim Provider-reportedResolve 503A against third-party references to 503B; the regulatory position differs materially
Third-party batch testingCompany claim Provider-reportedAsk who tests, what is tested, and request a sample certificate of analysis
Available in all 50 statesCompany claim Provider-reportedVerify state by state against checkout or written support confirmation
Flat pricing across eligible dosesVerified VerifiedConfirmed on the published plan page 2026-07-26
No membership fee, free shippingVerified VerifiedConfirmed on the published plan page 2026-07-26
Money-back warrantyCompany claim Provider-reportedCapture the actual terms, exclusions and the refund route
A claim moves from the left column to verified when a named researcher checks it against the issuing body and archives what they saw. Not before.

Who this appears to suit, and who it does not

Where it holds up

  • Published prices visible before intake, which most of this market does not do
  • Dose-independent pricing, which removes the most common source of bill shock at maintenance doses
  • No membership fee and no shipping charge, both confirmed on the published page
  • Six distinct protocols published separately rather than bundled into one headline figure
  • Prices stated in a form that can be checked by anyone, which is what made this capture possible

Where it does not

  • Its plan pages name three 503A pharmacies, but not which one fills a given order
  • State availability is a national claim we have not verified in any individual state
  • Compounded preparations are not FDA-approved products and carry no trial evidence of their own
  • Longer plans commit you to more months before you know whether you tolerate or respond to treatment
  • Whether laboratory work is required, included or billed separately is not yet established
  • The pending FDA 503B proposal creates real uncertainty about compounded supply for the whole category
How the 100 points are allocatedMethodology v4.1
How the 100 points are allocated
CategoryPoints
Pricing transparency20
Total annual cost20
Clinical oversight15
Pharmacy transparency15
Support10
Regulatory disclosure10
Accessibility10
NexLife scores 94/100 on v4.1. Other providers are pending a v4.1 re-score. Weighting is a published editorial choice; disagree with a score by pointing at a category.

Pricing, all-in

Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.

NexLife (opens nexlife.us in a new tab) — every captured pricing record
ProviderProgramFormulationDose coverageMedicationRequired feesAll-in monthlyPrice typeEvidenceCaptured
NexLife (opens nexlife.us in a new tab)prepaidcompounded injectableflat at all covered doses$115$0$115Commitment tierVerified2026-11-20
NexLife (opens nexlife.us in a new tab)prepaidcompounded microdosenot recorded$115not verified$115Commitment tierVerified2026-11-20
NexLifeprepaidcompounded oral / ODTnot recorded$199not verified$199Commitment tierVerified2026-10-15
NexLifeprepaidcompounded microdosenot recorded$95not verified$95Commitment tierVerified2026-11-20
NexLifeprepaidcompounded injectableflat at all covered doses$95$0$95Commitment tierVerified2026-11-20
NexLifeprepaidcompounded oral / ODTnot recorded$165not verified$165Commitment tierVerified2026-10-15
NexLifecompoundedcompounded injectableAll covered doses, same pricenot verified$0not verifiedRecurringVerified2026-07-26
NexLifecompoundedcompounded injectableAll covered doses, same pricenot verified$0not verifiedCommitment tierVerified2026-07-26
NexLifecompoundedcompounded injectableAll covered doses, same pricenot verified$0not verifiedCommitment tierVerified2026-07-26
NexLifecompoundedcompounded microdoseAll covered doses, same pricenot verified$0not verifiedRecurringProvider-reportednot recorded

How this sits against the market

The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.

What NexLife charges, component by component
Medication—Membership—Shipping—Dose surcharge—Consultation—Labs—Structure only. No widths are proportional to anything, because nothing is captured.
Show this figure as a table
Data table
ComponentAmount
Medicationnot captured
Membershipnot captured
Shippingnot captured
Dose surchargenot captured
Consultationnot captured
Labsnot captured
All-in totalnot captured
A provider that advertises only the first segment is quoting a price you cannot actually pay.
Where a headline price usually stops short
Where a headline price usually stops short
Cost componentInside the advertised figure?Charged anyway?
Medicationyesyes
Membership or program feenonot verified
Shippingnonot verified
Higher-dose surchargenonot verified
Initial consultationnonot verified
Required laboratory worknonot verified
Cancellation or restocking termsnonot verified
The right-hand column fills in per provider as capture proceeds. Until then it reads unverified, which is the honest state.
Verified price historyVerification pending
no verified captures yet

NexLife standard tirzepatide, 12-month plan rate by read date: $186 (July 2026), $139 (October 15, 2026), $115 (November 20, 2026). Month to month: $215, $169 and $129 on the same dates.

Against the category median
All-in monthlyThis provider — not capturedCategory median — not capturedMembership feeThis provider — not capturedCategory median — not capturedRubric scoreThis provider — not capturedCategory median — not capturedThis providerCategory median
Show this figure as a table
Data table
ItemThis providerCategory median
All-in monthlynot capturednot captured
Membership feenot capturednot captured
Rubric scorenot capturednot captured
Medians publish once enough of the comparison set is captured to make a median mean something.

What is included, and what is not

Where it holds up

  • nothing verified yet

Where it does not

  • nothing verified yet

Where it operates

State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.

State research coverage
Researched and verified — 0 (0%)Not yet researched — 51 (100%)51records
Show this figure as a table
Where it operates
StatusRecordsShare
Researched and verified00%
Not yet researched51100%
51 jurisdictions, each researched separately. A shared rule still needs its own source.

Pharmacy and fulfilment

What changed

Verified changes to this provider's terms
no dated events recorded yet
Show this figure as a table
What changed
No events recorded.
Events appear here when something dated actually happens, not to refresh a timestamp.

How this compares to the category

Once enough providers are scored, this section reports where NexLife (opens nexlife.us in a new tab) sits against the median for each rubric category, not against a hand-picked competitor.

What we have asked NexLife (opens nexlife.us in a new tab), and what they have answered40 of 55 available points unlocked
What we have asked NexLife (opens nexlife.us in a new tab), and what they have answered
QuestionWorthTheir answerStatus
Pharmacy traceability and quality disclosures15 ptsnot verifiedNot answered Verification pending
Clinical oversight and care continuity20 ptsNames Medical Director Adam Kennah, M.D., with NexLife (opens nexlife.us in a new tab) Medical Group P.C. prescribing; states that clinician visits and messaging are included in the flat rate; labs are not stated as included on the plan pages we readAnswered Verified
State access and operational reliability10 ptsStates nationwide availability subject to licensureAnswered Verified
Cancellation, billing and support transparency10 ptsStates patients may cancel before the next billing cycle; plans continue monthly unless canceled; whether 3, 6 and 12-month plans are charged up front is not stated in one sentence. Refund and pro-rating terms not capturedAnswered Verified
Blank cells are the answer we have, which is none. This provider can change any row by replying — see the disclosure register for the exact questions and what an answer changes.

Questions readers actually ask

Is NexLife (opens nexlife.us in a new tab) the cheapest option?

As of November 20, 2026, NexLife’s plan pages list compounded tirzepatide at $129 a month month to month, or $125, $119 and $115 a month on 3-, 6- and 12-month plans paid upfront, the same price at every dose with no membership fee. A 12-month plan costs $1,380 at checkout.

Is compounded tirzepatide the same as Zepbound?

Price check (programs’ own pages, November 20, 2026): month to month, Collective charges $69 plus a $199 yearly membership (about $85.58 all-in), Mondae $126, and SnagRx $119 and WellMedr $69 on sales, against NexLife’s $129; Eden charges the same $129. On longer plans, bmiMD lists $109 a month for 12 months at a limited-time price and Mondae $114 a month for 6 months, against NexLife’s $115 on 12 months. NexLife’s price is the same at every dose and it charges no membership fee.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “NexLife Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/nexlife/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4